bay area lyme foundation Archives - Bay Area Lyme Foundation

Bay Area Lyme Foundation Raises $900,000 at LymeAid 2026, Presenting Inaugural Neil L. Spector, MD, Legacy Award and $300,000 in Emerging Leader Grants

By Bay Area Lyme Foundation

FOR IMMEDIATE RELEASE

Bay Area Lyme Foundation Raises $900,000 at LymeAid 2026, Presenting Inaugural Neil L. Spector, MD, Legacy Award and $300,000 in Emerging Leader Grants

Dana Carvey Emceed; Chris Isaak Performed at Annual Gala Advancing Lyme and Tick-Borne Disease Research

PORTOLA VALLEY, Calif., May 27, 2026 — Bay Area Lyme Foundation, the nation’s leading public charity funder of Lyme disease research, raised $900,000 at LymeAid 2026, its annual benefit gala, over the Memorial Day weekend. The evening brought together leading scientists and clinicians, patients, and supporters united by a shared conviction: Lyme disease and other tick-borne infections should not be hard to diagnose, hard to treat, or easy to dismiss, and the science to change that is within reach.

Emmy Award-winning comedian Dana Carvey served as Master of Ceremonies. “This was my third time hosting LymeAid, and let me tell you, this community has more determination than my Church Lady character at a bake sale,” said Carvey.

Platinum-selling, GRAMMY-nominated singer Chris Isaak and his band Silvertone closed the evening in concert.

“Saturday night, LymeAid 2026 attendees came together in support of patients and to advance the research producing better diagnostics, new treatment approaches, and long overdue answers for patients with Lyme and other tick-borne diseases,” said David Walsey, Executive Director of Bay Area Lyme Foundation. “Bay Area Lyme exists to fund exactly that work, because this is a solvable problem and there are too many patients still searching for answers, losing years to inadequate diagnostics and treatment options.”

Empowering the Next Generation of Lyme Prevention Leaders: Tick-bite prevention tips for Girl Scouts

By Bay Area Lyme Foundation

Bay Area Lyme Spotlight series

“When it comes to tick bites, knowing how to protect yourself makes a big difference. Wear long sleeves and pants, use insect repellent, and check your body (and your pets!) carefully after outdoor play. We are excited to share this information, so more people can enjoy the outdoors safely.”

– Amara and Audrey

Bay Area Lyme is proud to recognize Girl Scouts Amara and Audrey, whose Silver Award project, Tick Tactics: Outsmarting Nature’s Sneakiest Pests, has been officially accepted by Girl Scouts of Northern California.

Their work transforms complex science into engaging, accessible education, helping young people understand the risks of tick-borne diseases and how to stay safe outdoors.

New Bay Area Lyme Foundation Study Shows Common FDA-Cleared Lyme Tests Miss 64-78% of Early Cases, Underscores Urgent Need for Improved Diagnostics

By Bay Area Lyme Foundation

FOR IMMEDIATE RELEASE

New Bay Area Lyme Foundation Study Shows Common FDA-Cleared Lyme Tests Miss 64-78% of Early Cases, Underscores Urgent Need for Improved Diagnostics

Research published in the Journal of Clinical Microbiology

PORTOLA VALLEY, Calif., April 21, 2026 –Bay Area Lyme Foundation, a national nonprofit and leading sponsor of tick-borne disease research in the US, today announced the publication of new research in the Journal of Clinical Microbiology based on data from its Lyme Disease Biobank. The study found that the commonly used FDA-cleared diagnostic testing methods available to providers and major national diagnostic laboratories are highly insensitive and miss 64-78% of early Lyme disease cases, including those who present with the characteristic erythema migrans (EM) Lyme rash.

“This study demonstrates that common two-tiered Lyme tests, utilized for decades, often fail to detect early Lyme disease and are leaving patients behind, highlighting a critical need for improved medical education on the limitations of current diagnostics,” said Liz Horn, PhD, MBI, Principal Investigator of Lyme Disease Biobank and lead author of the study. “Our findings also add to the evidence that improved diagnostics, ideally those that directly detect the bacteria that cause Lyme disease, are urgently needed.”

This large-scale, head-to-head study comparing 2 standard two-tiered testing (STTT) and 2 modified two-tiered testing (MTTT) diagnostic algorithms (the commonly used Lyme disease diagnostic algorithms) confirms that the sensitivity of two-tiered testing algorithms is low among patients with early infection. For the 107 early Lyme disease cases evaluated, the various testing algorithms missed 64-78% of early Lyme cases. Overall, only 39% (42/107) of participants with early Lyme disease were STTT or MTTT positive by any of the 4 algorithms.

New Peer-Reviewed Publication Highlights Evidence of Mother-to-Child-Transmission of Lyme Disease Bacteria During Pregnancy and Calls for Urgent Research

By Bay Area Lyme Foundation

FOR IMMEDIATE RELEASE

New Peer-Reviewed Publication Highlights Evidence of Mother-to-Child-Transmission of Lyme Disease Bacteria During Pregnancy and Calls for Urgent Research

New paper in Frontiers in Medicine reports results of meeting of international researchers at the Banbury Center of Cold Spring Harbor Laboratory

PORTOLA VALLEY, Calif., April 9, 2026 –Bay Area Lyme Foundation, a national nonprofit and leading sponsor of tick-borne disease research in the US, today announced publication of a new peer-reviewed article in Frontiers in Medicine examining the transmission of the Lyme bacteria during pregnancy. The publication points to observational research demonstrating that Lyme bacteria are capable of being transmitted from mother to unborn child and recognition by both the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) of the potential for mother-to-child transmission. With approximately 500,000 Americans diagnosed with Lyme disease each year and the related correlation of transmission during pregnancy being associated with serious adverse pregnancy outcomes, such as miscarriage, stillbirth, or congenital infection that occur in some cases, the paper concludes that the clinical impact of Lyme disease on pregnancy and infant health is an important public health issue that has been insufficiently studied.

“As an infectious disease pediatrician, I have seen firsthand the impact of Lyme disease in children and have suspected that the infection may have been passed from mother to child during pregnancy in a number of my patients, based on their medical histories,” said Charlotte Mao, MD, of Bay Area Lyme Foundation and a co-author of the study. “The first case studies of mother-to-child transmission were observed in the 1980s, yet decades later, we still lack sufficient research and clear, evidence-based guidance on Lyme in pregnancy and adverse pregnancy outcomes. This is an important public health issue and underscores the urgent need for rigorous studies to fully understand the risks and support patients and healthcare providers in making informed decisions that better protect maternal and infant health.”

Study authors highlight the great need for real-world studies clarifying how Lyme Borrelia, the bacteria that cause Lyme disease, the most common vector-borne disease in the US, behaves during pregnancy, and quantifying the outcomes for mothers and infants. Specifically, the paper suggests the creation of large, prospective studies of pregnant individuals with Lyme disease, including systematic long-term clinical follow-up of their children, as well as the importance of collecting biological samples from mothers, placentas, and infants through coordinated biorespositories for use in current or future studies.

A Leader Who Understands the Journey: Welcoming David Walsey as Bay Area Lyme Foundation’s New Executive Director

By Bay Area Lyme Foundation

Bay Area Lyme Spotlight Series

“Science drives our mission, but patient stories remind us why the science matters.”

– David Walsey

As David Walsey steps into his new role as Executive Director of Bay Area Lyme Foundation, he brings more than professional expertise. He brings lived experience of diagnostic uncertainty, immune dysfunction, co-infections, and the long arc many families travel before answers emerge. For patients, caregivers, and supporters of Bay Area Lyme, David’s leadership signals both continuity and momentum: a future rooted in rigorous science, compassionate leadership, and hope grounded in progress. “It’s been a long journey to get here,” David says. “We’ve spent nearly a decade navigating tick-borne disease as a family. That experience changed everything for us.” Dana Parish interviewed David as part of our Ticktective^™ video podcast series. Watch or listen to the complete interview.

When Symptoms Don’t Fit the Textbook

Nearly ten years ago, David’s son began experiencing a constellation of symptoms that defied easy explanation. Despite multiple medical evaluations, no unifying diagnosis emerged. When Lyme disease was finally identified, the family initially felt relief. “I thought this was a solvable, short-term problem,” David recalls. “You treat it, and life goes back to normal.”

Improving Lyme Diagnostics, Biomarkers, and Treatment: Inside Dr. Peter Gwynne’s Research

By Bay Area Lyme Foundation

Bay Area Lyme Leading the Way series

“I wanted to be doing work that was driven by clinical need… and there are a lot of clinical needs in Lyme disease.”

– Peter Gwynne, PhD

For too many people with Lyme disease, the journey begins with uncertainty. A missed rash. A negative test. Symptoms that don’t make sense. A diagnosis that comes too late, or not at all. Bay Area Lyme Foundation believes this must change. And we believe change happens through funding rigorous science, innovative thinking, and supporting researchers willing to tackle the hardest questions head-on.

One of those scientists is Tufts researcher Peter Gwynne, PhD, a microbiologist whose work sits at the cutting edge of Lyme research and is the recipient of our 2022 Emerging Leader Award. We spoke with Dr. Gwynne to get an inside look at his work and understand how this may impact Lyme patients in the future. His focus is simple to state but complex to achieve: develop better diagnostics, identify meaningful biomarkers, and move the field toward treatments and even prevention strategies that could fundamentally reshape how Lyme disease is understood and managed.

Drawn to Lyme by the Urgency of the Need

Dr. Gwynne did not begin his career in Lyme disease. He trained in molecular microbiology, studying pathogens such as Salmonella and Staphylococcus, the bacteria responsible for serious infections, including those often acquired in hospital settings. But over time, he found himself seeking work that could make a tangible difference for patients.

We Need a New Generation of Lyme Doctors: James Bruzzese, MD, is Leading the Way

By Bay Area Lyme Foundation

Bay Area Lyme Spotlights Series

“Some institutions are evolving in research and education, but it’s not translating to clinical practice.”

– James Bruzzese, MD

When James Bruzzese, MD, talks about Lyme disease, he doesn’t speak in abstractions. He speaks as a brother who watched his sister lose her ability to walk; a son who watched his father leave his job to become a full-time caregiver; and as a medical student who sat in lecture halls knowing that what was being taught about Lyme and tick-borne disease was grossly incomplete.

Now, as a young physician preparing to open a practice dedicated to treating Lyme and tick-borne disease patients in New York, James represents something the Lyme community urgently needs: a new generation of doctors who understand that Lyme is real, that patients deserve better, and that the status quo must be challenged.

“It Was Traumatic. We Thought We Might Lose Her.”

Bay Area Lyme Foundation Highlights Research Leadership and Momentum in Tick-Borne Disease, Names New Executive Director

By Bay Area Lyme Foundation

FOR IMMEDIATE RELEASE

Bay Area Lyme Foundation Highlights Research Leadership and Momentum in Tick-Borne Disease, Names New Executive Director

Milestones include FDA-cleared diagnostics enabled by Lyme Disease Biobank, the launch of Bay Area Lyme Ventures, and 10 years since Lyme Disease Biobank provided its first samples, advancing the field

PORTOLA VALLEY, Calif., February 11, 2026 –Bay Area Lyme Foundation, a national nonprofit and leading sponsor of tick-borne disease research, today reflected on concrete progress in 2025 that demonstrates the maturation of more than a decade of investment in diagnostics, therapeutics, and research infrastructure for Lyme and other tick-borne diseases. As Bay Area Lyme Foundation-supported programs advance towards being available for clinicians and patients, the organization announced David A. Walsey, JD, LLM, as Executive Director. He has extensive experience offering strategic guidance to life sciences companies and a personal connection to Lyme disease that will help guide the foundation’s next phase of scientific translation and organizational growth.

In 2025, Bay Area Lyme Foundation reached an important inflection point as new diagnostic tests enabled by the foundation’s Lyme Disease Biobank secured FDA clearance. These new tests highlight the potential to move from discovery-stage research toward tools that can meaningfully improve patient care. The organization also launched Bay Area Lyme Ventures, an investment arm designed to help promising diagnostics and therapeutics move more efficiently from the laboratory into real-world use, while also creating the opportunity for returns to support future Bay Area Lyme Foundation research. This progress underscores the importance of the more than $30 million in research Bay Area Lyme Foundation has invested at leading academic and medical institutions such as Stanford, Johns Hopkins, Tulane, and Duke. Research supported by the foundation has produced over 70 peer-reviewed scientific publications and sustained collaboration across top research centers nationwide.

Meet David Walsey: Our New Executive Director

By Bay Area Lyme Foundation

David A. Walsey, JD, LLM

David Walsey joined Bay Area Lyme Foundation as Executive Director in 2025. He is a strategic biotech leader with 25 years of experience advancing corporate objectives through strategy, communications, financing, and investor initiatives for public companies. Most recently, David served as Senior Vice President, Corporate Affairs at MEI Pharma, leading programs spanning corporate strategy, investor relations, and corporate communications. He previously held senior roles at Alder Biopharmaceuticals, Optimer Pharmaceuticals, Sarepta Therapeutics (formerly AVI BioPharma), Arena Pharmaceuticals, and Maxim Pharmaceuticals, and worked at agencies including Real Chemistry (formerly W20 Group), The Ruth Group, and Noonan Russo. He began his career as an attorney in private practice in New York City and holds an LL.M. in Taxation from New York University School of Law, a J.D. from Brooklyn Law School, and a B.A. from Franklin and Marshall College.

Watch Now

Dr. Casey Kelley: From Lyme & Mold to Optimum Health

By Bay Area Lyme Foundation

Bay Area Lyme Spotlight Series

Click here to watch or listen now

In a powerful Ticktective™ episode, host Dana Parish sits down with Casey Kelley, MD, Founder and Medical Director of Case Integrative Health, to unpack the complex world of Lyme disease, mold toxicity, environmental illness, and whole-body healing. Dr. Kelley had her own health journey with chronic fatigue, POTS, and other symptoms that led her to specialize in Lyme, tick-borne diseases, mold illness, long COVID, and other complex chronic illnesses. She brings clarity, compassion, and years of integrative and functional medicine experience to help patients understand what’s driving persistent symptoms and what true recovery can look like.

“The nervous system is utterly important to healing. And that entire system gets really thrown off with chronic infections exactly the same way that trauma with a capital T will cause dysfunction in the system.”

– Casey Kelley, MD